Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 15/20 | 0.74 |
| ▸ | ADRA2B | P18089 | 15/20 | 0.74 |
| ▸ | ADRA2C | P18825 | 15/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 15/20 | 0.74 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18826054 | 0.91 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL29357620 | 0.85 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL304971 | 0.85 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL203964 | 0.84 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL30249868 | 0.84 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826070 | 0.82 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826064 | 0.79 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL31683943 | 0.79 | ADRA2A (0.72) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826059 | 0.78 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL18826071 | 0.77 | ADRA2A (0.68) | ADRA2AADRA2BADRA2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12414937-B2 | Local and regional anesthesia and analgesia | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-09-16 | — | — | US | claimed |
| EP-3370718-B1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIV LOUISVILLE RES FOUND INC (US) | 2021-01-27 | — | — | EP | claimed |
| US-20200383953-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2020-12-10 | — | — | US | claimed |
| EP-3370718-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | University Of Louisville Research Foundation, Inc. (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017079734-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2017-05-11 | — | — | WO | claimed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | claimed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | claimed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | claimed |
| EP-3370718-B1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIV LOUISVILLE RES FOUND INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3370718-B1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIV LOUISVILLE RES FOUND INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200383953-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2020-12-10 | — | — | US | disclosed |
| EP-0310745-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | ORION-YHTYMÄ OY (FI) | 1993-01-27 | — | — | EP | disclosed |
| EP-0183492-B1 | SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR PREPARATION AND USE | Farmos-Yhtyma Oy (FI) | 1989-11-15 | — | — | EP | disclosed |
| EP-0310745-A2 | Substituted imidazole derivatives and their preparation and use | ORION-YHTYMÄ OY (FI) | 1989-04-12 | — | — | EP | disclosed |
| US-4689339-A | 4-dihydroinden-2-yl-, 4-tetrahydronaphth-2-yl-, and 4-dihydrobenzofuran-2-ylimidazoles, useful to block α2 -adrenergic receptors | FARMOS YHTYMA OY (FI) | 1987-08-25 | — | — | US | disclosed |
| EP-0183492-A1 | Substituted imidazole derivatives and their preparation and use | Farmos-Yhtyma Oy (FI) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383953-A1 | LOCAL AND REGIONAL ANESTHESIA AND ANALGESIA | OPRL1, OPRK1, OPRM1 | ADRA2A 5/4885ADRA2B 8/4885ADRA2C 4/4885 |
| US-12414937-B2 | Local and regional anesthesia and analgesia | OPRL1, OPRK1, OPRM1 | ADRA2A 5/4885ADRA2B 8/4885ADRA2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.